Equities

Guangzhou LBP Medicine Science & Technology Co Ltd

688393:SHH

Guangzhou LBP Medicine Science & Technology Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CNY)20.19
  • Today's Change1.02 / 5.32%
  • Shares traded4.11m
  • 1 Year change-24.38%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments120266637
Total Receivables, Net255250221
Total Inventory756341
Prepaid expenses131510
Other current assets, total1040.91--
Total current assets568595909
Property, plant & equipment, net314327277
Goodwill, net263030
Intangibles, net237.255.85
Long term investments42339666
Note receivable - long term------
Other long term assets----62
Total assets1,4001,3931,366
LIABILITIES
Accounts payable373350
Accrued expenses323627
Notes payable/short-term debt21147.00
Current portion long-term debt/capital leases2.003.262.54
Other current liabilities, total182820
Total current liabilities110114107
Total long term debt5.187.242.85
Total debt282512
Deferred income tax141613
Minority interest(21)(2.35)8.76
Other liabilities, total282930
Total liabilities136164162
SHAREHOLDERS EQUITY
Common stock949393
Additional paid-in capital749741734
Retained earnings (accumulated deficit)421394377
Treasury stock - common------
Unrealized gain (loss)--(0.38)--
Other equity, total------
Total equity1,2641,2291,204
Total liabilities & shareholders' equity1,4001,3931,366
Total common shares outstanding949393
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.